TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pasos Saludables: A Pilot Intervention to Prevent Obesity and Diabetes Among Latino Farm Workers
Brief Summary: This is a study to assess the effectiveness of a culturally appropriate behavioral intervention to reduce obesity levels and ultimately the risk of developing diabetes type II in immigrant Latino farm workers. Workers enrolled in a 2:1 ratio by random allocation into an intervention or control arm of the study. The intervention participants received weekly classes for 10 weeks with education on diabetes, diet and physical activity and practical exercises. Both control and intervention were measured for weight, waist circumference, fasting blood glucose and interviewed before and after the study intervention. The main hypothesis was that intervention, but not control participants, would experience reduction in body measurements after the intervention.


Options:
A: Arm Label: Worksite Environmental Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight gain prevention | Arm Label: No-contact control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight gain prevention; Assigned to Arm(s): Worksite Environmental Intervention
B: Arm Label: Internet-based maintenance program; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based maintenance program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based maintenance program; Assigned to Arm(s): Internet-based maintenance program
C: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Behavioral Intervention; Assigned to Arm(s): Behavioral intervention, Control
D: Arm Label: 1-800-QUIT-NOW Telephone Hotline; Type: OTHER; Interventions: Other: 1-800-QUIT-NOW Telephone Hotline | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Web-Based Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: 1-800-QUIT-NOW Telephone Hotline; Assigned to Arm(s): 1-800-QUIT-NOW Telephone Hotline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease
Brief Summary: Cardiovascular disease is the primary cause of death in patients with end stage renal disease (ESRD). New research suggests that the high risk of death may be partly due to high levels of fibrosis and a loss of small blood vessels in the heart of patients with dialysis-dependent ESRD. This study is designed to compare the effects of two different drugs, spironolactone and L-arginine, with placebo on structure and function of the heart in individuals with dialysis-dependent ESRD.


Options:
A: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Spironolactone + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone, Drug: Placebo | Arm Label: Double Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone + L-arginine; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone, Dietary Supplement: L-arginine | Arm Label: L-arginine + Placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: L-arginine, Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone + L-arginine, Spironolactone + Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: L-arginine; Assigned to Arm(s): L-arginine + Placebo, Spironolactone + L-arginine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double Placebo, L-arginine + Placebo, Spironolactone + Placebo
C: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Body Mass Index on Etonogestrel Levels in Women Using the Single-rod Contraceptive Implant
Brief Summary: Two-thirds of young women in the United States are overweight or obese. This excess weight may affect how their body metabolizes drugs such as different birth control methods. There is a not a lot of research about how excess weight could affect the hormone levels of the contraceptive implant. Methods like the implant contain only progesterone, which is a hormone that does not increase a woman's risk of blood clot. These methods would be preferred for overweight and obese women because excess weight also increases a woman's risk of blood clot.

The investigators propose a study comparing blood hormone levels of women using the implant for at least twelve months and in all weight categories. The investigators hope to show that all women, regardless of weight, will have hormone levels high enough to prevent pregnancy.


Options:
A: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15
B: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane
C: Arm Label: Normal weight women; Type: N/A; Interventions: N/A | Arm Label: Overweight women; Type: N/A; Interventions: N/A | Arm Label: Obese women; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country
Brief Summary: The study hypothesis was In women with gestational diabetes and type 2 diabetes in pregnancy metformin treatment compared with insulin will result in better perinatal and maternal outcome and improved treatment acceptability with low or noadditional insulin requirement.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: insulin; Assigned to Arm(s): insulin
B: Arm Label: Levemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Levemir, NPH
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
D: Arm Label: metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): insulin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country
Brief Summary: The study hypothesis was In women with gestational diabetes and type 2 diabetes in pregnancy metformin treatment compared with insulin will result in better perinatal and maternal outcome and improved treatment acceptability with low or noadditional insulin requirement.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo
B: Arm Label: Glyburide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
D: Arm Label: metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): insulin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees
Brief Summary: This study aims to assess the uptake, effectiveness, and cost-effectiveness of a scalable walking programme for full-time employees both with and without incentives.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: No training | Intervention Type: BEHAVIORAL; Name: Physical training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: No training; Assigned to Arm(s): 2
B: Arm Label: Control Group; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Programme Only Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Other: Usual Care | Arm Label: Cash Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Cash Incentives, Other: Usual Care | Arm Label: Charitable Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Charitable Incentives, Other: Usual Care | Intervention Type: DEVICE; Name: Fitbit; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Programme Only Group | Intervention Type: BEHAVIORAL; Name: Cash Incentives; Assigned to Arm(s): Cash Incentive Group | Intervention Type: BEHAVIORAL; Name: Charitable Incentives; Assigned to Arm(s): Charitable Incentive Group | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Control Group, Programme Only Group
C: Arm Label: HeartWare® VAS; Type: EXPERIMENTAL; Interventions: Device: HeartWare® VAS | Intervention Type: DEVICE; Name: HeartWare® VAS; Assigned to Arm(s): HeartWare® VAS
D: Arm Label: Stair walking; Type: EXPERIMENTAL; Interventions: Behavioral: Stair walking | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stair walking | Intervention Type: BEHAVIORAL; Name: Stair walking; Assigned to Arm(s): Control, Stair walking

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of the Auto-acupressure for Diminishing Neck Pain of Benign Origin
Brief Summary: The purpose of this study is to evaluate the effectiveness of the auto-acupressure (digital pressure in points of acupuncture) added to the conventional treatment.


Options:
A: Arm Label: Waiting list control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dry Cupping or fire cupping | Intervention Type: PROCEDURE; Name: Dry Cupping or fire cupping; Assigned to Arm(s): Treatment group
B: Arm Label: Massage Dose 1; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 2; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 3; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 4; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 5; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 6; Type: EXPERIMENTAL; Interventions: Other: Massage | Intervention Type: OTHER; Name: Massage; Assigned to Arm(s): Massage - Dose 2, Massage - Dose 3, Massage - Dose 4, Massage - Dose 5, Massage - Dose 6, Massage Dose 1
C: Arm Label: Auto-acupressure; Type: EXPERIMENTAL; Interventions: Other: Auto-acupressure | Arm Label: Conventional treatment; Type: OTHER; Interventions: Other: Conventional treatment | Intervention Type: OTHER; Name: Auto-acupressure; Assigned to Arm(s): Auto-acupressure | Intervention Type: OTHER; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Combined Physiotherapy Protocol | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Other: EYE-CERVICAL RE-EDUCATION PROGRAM | Intervention Type: OTHER; Name: EYE-CERVICAL RE-EDUCATION PROGRAM; Assigned to Arm(s): Experimental Group | Intervention Type: OTHER; Name: Combined Physiotherapy Protocol; Assigned to Arm(s): Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies
Brief Summary: Age is a risk factor for graft-versus-host disease (GVHD) after human leukocyte antigen (HLA)-matched sibling allogeneic stem cell transplantation (allo-SCT). The incidence of acute GVHD is significantly higher in patients at 40 years of age or more than those at 18 to 39 years of age after allo-SCT. It was found that Anti-thymocyte globulins can be used for prophylaxis of both acute and chronic GVHD after allo-SCT.Prophylaxis of GVHD using ATG in patients at 40 years of age or more in matched sibling allo-SCT settings might significantly decrease the incidence of acute and chronic GVHD and the incidence of late effect after transplantation.


Options:
A: Arm Label: ATG 7.5mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Arm Label: ATG 10mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Intervention Type: DRUG; Name: ATG; Assigned to Arm(s): ATG 10mg/kg, ATG 7.5mg/kg
B: Arm Label: ATLG group; Type: N/A; Interventions: N/A | Arm Label: no ATLG group; Type: N/A; Interventions: N/A
C: Arm Label: A; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Arm Label: B; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): A | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): B
D: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs
Brief Summary: To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of the lower limbs.

For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of the lower limbs will be compared with that of fondaparinux.


Options:
A: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
B: Arm Label: SRI 15mg (15 mL/min ≤ CLCR < 20mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Arm Label: MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min); Type: EXPERIMENTAL; Interventions: Drug: 30mg DU-176b | Arm Label: Fondaparinux (20 mL/min ≤ CLCR < 30mL/min); Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: SRI 15mg (20 mL/min ≤ CLCR < 30mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Intervention Type: DRUG; Name: 15mg DU-176b; Assigned to Arm(s): SRI 15mg (15 mL/min ≤ CLCR < 20mL/min), SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) | Intervention Type: DRUG; Name: 30mg DU-176b; Assigned to Arm(s): MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux: | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fondaparinux:; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 3
D: Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial
Brief Summary: The University of Sao Paulo Department of Otorhinolaryngology developed prototypes for a digital new hearing aid with an integrated sound generator. These prototypes assist both hearing rehabilitation (about 10% of the population) and tinnitus sufferers (about 17% of the population).

Currently, the Brazilian Public Heath Care does not have any such hearing aids. So, the development of devices for the hearing rehabilitation as well as the treatment of tinnitus represents an advance in the implementation of Public Policies in Brazil.

The aim of this study is to compare the efficacy of the hearing aid with an integrated sound generator and amplification alone for tinnitus control in patients with tinnitus associated hearing loss.


Options:
A: Arm Label: Specialized Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialized Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specialized Care; Assigned to Arm(s): Specialized Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: STAR2; Type: ACTIVE_COMPARATOR; Interventions: Other: reactive auditory training | Arm Label: Treasure Hunter; Type: EXPERIMENTAL; Interventions: Other: Interactive auditory training | Arm Label: Submarine; Type: EXPERIMENTAL; Interventions: Other: Interactive auditory training | Intervention Type: OTHER; Name: reactive auditory training; Assigned to Arm(s): STAR2 | Intervention Type: OTHER; Name: Interactive auditory training; Assigned to Arm(s): Submarine, Treasure Hunter
C: Arm Label: Group 1 : G_1; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group 2 :G_2; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group3 : G_3; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group 4 : G_4; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group5 : G_5; Type: PLACEBO_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Intervention Type: DEVICE; Name: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset; Assigned to Arm(s): Group 1 : G_1, Group 2 :G_2, Group 4 : G_4, Group3 : G_3, Group5 : G_5
D: Arm Label: control; Type: OTHER; Interventions: Device: hearing aids with only amplification | Arm Label: sound generator; Type: EXPERIMENTAL; Interventions: Device: sound generator | Intervention Type: DEVICE; Name: sound generator; Assigned to Arm(s): sound generator | Intervention Type: DEVICE; Name: hearing aids with only amplification; Assigned to Arm(s): control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial
Brief Summary: The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial. However, the dual inhibition has not been studied during heart failure decompensation or even when low cardiac output is present.

The objective of this study was to assess the effects of add-on therapy with angiotensin receptor blocker on plasma B-type natriuretic peptide levels and hemodynamic measurements in heart failure patients with low cardiac output during hospitalization for decompensation.

This was a randomized, double-blind, placebo-controlled clinical trial.


Options:
A: Arm Label: Losartan; Type: EXPERIMENTAL; Interventions: Drug: Losartan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tilarginine Acetate Injection intravenous infusion; Assigned to Arm(s): N/A

Answer: A